NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.50 +0.02 (+0.03%) GOLD FUTURES
2,322.40 -8.80 (-0.38%) DOW
38,866.17 +13.90 (+0.04%) Bitcoin GBP
50,483.02 -244.06 (-0.48%)
LGND May 2024 110.000 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 110.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
ZacksRocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
ZacksApellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
Business WireLigand and Agenus Enter Into $100 Million Royalty Financing Agreement
JUPITER, Fla. and LEXINGTON, Mass., May 07, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with met
